NSIS-B.CO Novonesis (Novozymes) A/S

Basic Materials Chemicals Copenhagen Exchange
465.30 DKK
Close of Oct 29, 2026
336.12 481.50
Market cap
DKK 219B
P/E
40.5x
P/B
2.28x
ROE
6.6%
Dividend yield
1.42%
Fundamental score
2.3/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is NSIS-B.CO undervalued?

Graham number
Price465.30
Graham value229.59
Premium102.7%

NSIS-B.CO trades 102.7% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Novonesis (Novozymes) A/S fundamental analysis

10 of 22 checks passed

ROE 0/2

Low return on equity (6.6%), below 10%.

ROA 1/1

Return on assets (4.5%) is above the industry median (4.2%).

Profit Consistency 2/2

Profitable for 10 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share did not grow over the past 5 years.

Earnings Acceleration 1/1

Last year's EPS growth (87.9%) is above the 5-year average (-34.1% a year).

Earnings Growth vs Industry 1/1

Last year's EPS growth (87.9%) is above the industry median (-1.9%).

Revenue Growth 2/2

Revenue grew 20.8% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 0/1

Current assets do not cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (27.5%), 40% or less.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 1/1

Operating cash flow covers 20% of total debt.

Interest Coverage 1/1

EBIT is 13.6x against interest expense, well covered.

PE vs Market 0/1

PE (46.2x) is above the market median (17.0x).

PE vs Industry 0/1

PE (46.2x) is above the industry median (12.5x).

PBV 0/1

Price to book (2.6x) is above the industry median (1.1x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 120.2, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

Dividend yield (1.5%) is in the bottom 25% of dividend payers in the market.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 1/1

Payout ratio is 69.1%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Novonesis (Novozymes) A/S stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Novonesis (Novozymes) A/S

Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. It provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as precision protein and early lie nutrition. The company also offers bioenergy solutions including biodiesel; biogas from agricult…

Full company profile